The earnings call reflects a company undergoing significant leadership transition and strategic reassessment. While there are positives in the form of reduced operating expenses and net loss, major challenges remain, particularly around delays in clinical trials and resource constraints. The uncertainty in achieving future milestones further complicates the outlook.

Company Guidance -

Q3 2025

During the Vicarious Surgical's 2025 Second Quarter Earnings Call, the company provided forward-looking guidance with several key metrics. Notably, total operating expenses for Q2 2025 were $13.5 million, marking a 24% decrease compared to $17.7 million in Q2 2024. Research and development expenses were $9.1 million, a decrease from $10.9 million in the same quarter the previous year. General and administrative expenses were reported at $4.1 million, down from $5.6 million in Q2 2024, while sales and marketing expenses were $300,000, significantly lower than the $1.2 million spent in Q2 2024. The company reported a GAAP net loss of $13.2 million or $2.23 per share for Q2 2025, compared to a net loss of $15.2 million or $2.59 per share in Q2 2024. The non-GAAP adjusted net loss was $13.3 million or $2.23 per share, improving from a loss of $16.8 million or $2.86 per share in Q2 2024. Cash, cash equivalents, and short-term investments totaled approximately $24 million at the end of the quarter, with a cash burn rate of around $13.4 million for Q2. The company expects a full-year 2025 cash burn of approximately $50 million, emphasizing disciplined capital allocation. The guidance also highlighted a strategic shift, focusing on completing a fully integrated production-equivalent system for their surgical platform, with a timeline reassessment over the next 4 to 6 weeks, impacting future clinical trial milestones and FDA submissions.

Leadership Transition

Stephen From has joined Vicarious Surgical as the new CEO, bringing a strong track record in healthcare and medtech industries. This leadership change is seen as a pivotal moment for the company's evolution.

Reduced Operating Expenses

Total operating expenses for Q2 2025 were $13.5 million, a 24% decrease compared to $17.7 million in Q2 2024. This includes a decrease in research and development expenses from $10.9 million in Q2 2024 to $9.1 million in Q2 2025.

Decreased Net Loss

The GAAP net loss for Q2 2025 was $13.2 million, or $2.23 per share, compared to a net loss of $15.2 million, or $2.59 per share, in Q2 2024.

Vicarious Surgical (RBOT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

RBOT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 10, 2025	2025 (Q3)	-2.33 / -	-2.877	―	―	―
Aug 12, 2025	2025 (Q2)	-2.50 / -2.23	-2.86	22.03% (+0.63)	―
May 12, 2025	2025 (Q1)	-2.48 / -2.58	-2.7	4.44% (+0.12)	―
Mar 17, 2025	2024 (Q4)	-2.69 / -2.43	-2.1	-15.71% (-0.33)	―
Nov 12, 2024	2024 (Q3)	-2.58 / -2.88	-3.6	20.08% (+0.72)	―
Aug 12, 2024	2024 (Q2)	-2.72 / -2.86	-4.8	40.42% (+1.94)	―
Apr 29, 2024	2024 (Q1)	-2.85 / -2.70	-5.1	47.06% (+2.40)	―
Mar 04, 2024	2023 (Q4)	-3.75 / -2.10	-4.8	56.25% (+2.70)	―
Nov 13, 2023	2023 (Q3)	-4.21 / -3.60	-5.4	33.33% (+1.80)	―
Jul 27, 2023	2023 (Q2)	-4.28 / -4.80	-4.8	0.00% (0.00)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

RBOT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$10.35	$7.83	-24.35%
May 12, 2025	$8.87	$7.90	-10.94%
Mar 17, 2025	$9.63	$8.20	-14.85%
Nov 12, 2024	$11.14	$9.15	-17.86%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Vicarious Surgical (RBOT) report earnings?

Vicarious Surgical (RBOT) is schdueled to report earning on Nov 10, 2025, After Close (Confirmed).

What is Vicarious Surgical (RBOT) earnings time?

Vicarious Surgical (RBOT) earnings time is at Nov 10, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is RBOT EPS forecast?

RBOT EPS forecast for the fiscal quarter 2025 (Q3) is -2.33.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing